Multiple Sclerosis 
The MD Magazine Multiple Sclerosis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


New Data on Teriflunomide, Alemtuzumab Announced at AAN 2017
Follow-up data from TOPIC, CARE-MS II trials positive for the two MS drugs.
Aaron Miller, MD, Hideki Garren, MD, and Kate Dawson, MD, discuss the top findings for teriflunomide, ocrelizumab, and tecfidera plus tysabri for patients with multiple sclerosis.
“This appears to be a very safe and effective drug, and is a valuable part of our therapeutic armamentarium. I don’t think teriflunomide addresses all the unmet needs in MS, in fact, no drug meets all the unmet needs, but this is a very well tolerated oral agent.”
The nearly 7-year extension trial presented a 47% reduction overall in conversion to clinically definite MS with those patients who had been on 14mg of teriflunomide from the beginning.
Ocrevus reduced all 3 aspects of relapsing MS disease: reduction relapses, reduction disability, and reduction lesions within the brain quite substantially.
Tecfidera and Tysabri can provide MS patients with positive outcomes.
Researchers previously only considered ALS as one illness, but new knowledge has changed that mentality and has shown experts they need to personalize treatment approaches. “It’s important to understand the disease in different groups of people.”
Preliminary results hint at a new type of progressive MS treatment.
Multiple sclerosis is an expensive condition to treat in the US.

Most Popular


$vacMongoViewPlus$ $vAR$